Skip to main content

You are here:

SELECT

This Clinical trial will investigate if Semaglutide has an effect on reducing cardiovascular events e.g. heart attack or stroke in overweight or obese patients.

Key Eligibility Criteria

Male or Female ≥45 years
Body mass index (BMI) ≥27kg/m2
Have established cardiovascular disease as evidenced by at least one of the following:

– Prior Myocadial Infarction (Heart Attack)
– Prior Stroke (Ischemic or Haemorrhagic Stroke)
– Symptomatic Peripheral Arterial Disease (PAD)

Therapeutic Area
Obesity
Type of Study
Phase 3b Clinical Trial
Study Status
Open Recruiting
Sponsor
NovoNordisk
Principal Investigator
Professor Donal O'Shea
Contact
laura.feeney@ucd.ie